Browse News
Filter News
Found 37 articles
-
Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
8/11/2022
Vaxxinity, Inc. today reported financial results for the second quarter ended June 30, 2022.
-
The annual Alzheimer’s Association International Conference (AAIC) is running from July 31-August 4 at the San Diego Convention Center and online. Here are some of the highlights presented so far.
-
Vaxxinity’s Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates
8/2/2022
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced data demonstrating durable lowering of low-density lipoprotein (LDL) cholesterol in non-human primates and the selection of VXX-401 to pursue as its anti-PCSK9 vaccine candidate to treat hypercholesterolemia.
-
Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates at the 2022 Alzheimer's Association International Conference (AAIC)
8/1/2022
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (AD) during a poster session at the 2022 Alzheimer's Association International Conference (AAIC).
-
Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines
7/25/2022
Vaxxinity, Inc. Chief Executive Officer Mei Mei Hu will participate as a speaker at the White House Summit on the Future of COVID-19 Vaccines.
-
MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer
7/18/2022
MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the addition of Kate Surdez as Chief Human Resources Officer (CHRO), effective today.
-
Vaxxinity to Participate at the Jefferies Healthcare Conference
6/2/2022
Vaxxinity, Inc. announced that Mei Mei Hu, President and Chief Executive Officer of Vaxxinity, will participate in a fireside chat at the Jefferies Healthcare Conference, being held in New York, NY on Thursday, June 9, 2022 at 11:30 a.m. ET.
-
Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates
5/9/2022
Vaxxinity, Inc. today reported financial results for the first quarter ended March 31, 2022.
-
Vaxxinity to Participate at the Bank of America Securities 2022 Healthcare Conference
5/5/2022
Vaxxinity, Inc. announced that Mei Mei Hu, President and Chief Executive Officer of Vaxxinity, will participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference, being held in Las Vegas, Nevada on Thursday, May 12, 2022 at 10:40 a.m. PT.
-
Over the past several years, The Lone Star State has been growing in significance as a life sciences hub. Now the industry is flocking to Hays County and its Innovation Corridor.
-
Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease
5/2/2022
Vaxxinity, Inc. (Nasdaq: VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease.
-
Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease
4/28/2022
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced it has completed patient enrollment for Part B of its ongoing Phase 1 clinical trial of UB-312 in Parkinson’s disease (PD).
-
CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants
4/6/2022
The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), today announced that they will co-fund the ongoing global pivotal Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match’ – booster dose. CEPI will provide up to $9.25m in funding.
-
Sigyn Therapeutics Appoints Ajay Verma, M.D., Ph.D. to its Scientific Advisory Board
3/31/2022
Sigyn Therapeutics, Inc. today announced the appointment of Ajay Verma, M.D., Ph.D.to its Scientific Advisory Board.
-
Vaxxinity Announces First Participant Dosed in Phase 3 Study of Next-Generation COVID-19 Vaccine Booster
3/28/2022
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that it has begun dosing participants in a Phase 3 pivotal trial of UB-612, the Company’s next-generation COVID-19 booster candidate.
-
BioSpace Movers & Shakers, March 25
3/25/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates
3/24/2022
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Vaxxinity Appoints Dr. Peter Powchik to Board of Directors
3/21/2022
Vaxxinity, Inc. today announced that Peter Powchik, M.D. is joining its Board of Directors and will be retiring as Vaxxinity’s Executive Vice President, Research & Development.
-
Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern
2/11/2022
Vaxxinity, Inc. (Nasdaq: VAXX), today announced results from studies demonstrating the ability of UB-612, its COVID-19 vaccine candidate, to elicit a broad immune response against multiple variants of concern, and specifically more than three-times higher titers of neutralizing antibodies against the Omicron variant of SARS-CoV-2 than an approved mRNA vaccine with boosters.
-
Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312
1/12/2022
Vaxxinity, Inc. (Nasdaq: VAXX), today announced that the first patient with Parkinson’s disease (PD) has been dosed with UB-312 in Part B of a double-blinded, placebo-controlled Phase 1 clinical trial, following completion of Part A of the Phase 1 trial in healthy volunteers.